The Russian Health Ministry has authorized the Smorodintsev Research Institute of Influenza operating under its aegis to begin clinical trials of the Corfluvec nasal vaccine for Covid-19 prophylaxis, according to information available in the state register of medicines.
Phase I-II clinical trials will be conducted on 250 volunteers aged from 18 to 60.
The trials will be held at two medical centers in St. Petersburg, namely, the Smorodintsev Research Institute of Influenza and the Pavlov First St. Petersburg State Medical University, until December 30, 2022.
Back on April 1, 2022, the Russian Health Ministry registered the first nasal Covid-19 vaccine designed by the Gamaleya Center. Same as Sputnik V (which, however, is administered intramuscularly), this is a two-component adenoviral vector vaccine. The drug is administered into the nasal cavity by a special spray nozzle at a three-week interval, i.e. in the "prime-boost" mode.
Also, on June 5, 2022, the Russian Health Ministry registered the Salnavac two-component Covid-19 nasal vaccine designed by Generium. This is a combined vector vaccine in the form of a nasal spray.
